

## PACIFIC EDGE APPOINTS CHIEF OPERATING OFFICER

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) is pleased to announce the appointment of Demi Stefanova as Chief Operating Officer, effective from 21 June 2021.

This is a new role for Pacific Edge as the company strengthens its leadership team to meet the demands of the business as it grows. Pacific Edge is focused on leveraging recent milestones to drive continued commercial adoption of its family of Cxbladder bladder cancer diagnostic tests in its targeted markets, particularly the United States. The COO will have responsibility for global manufacturing and compliance functions, and in particular, the manufacturing and operational goals and tactical plans for maximising operational efficiency, optimising production levels and driving operational excellence, while at the same time ensuring that the company meets and exceeds customer expectations.

Demi is a senior executive with a wealth of experience establishing and running manufacturing operations in highly regulated environments. She has specific experience in Cancer Medical Research Operations, Biotechnology, Supply Chain & Logistics and Pharmaceutical and GMP Engineering. Demi has worked for a number of global businesses, executing global change and transformation programmes.

Demi has held senior leadership roles since 2004. Her most recent role was as Head of Operations of the Children Medical Research Institute in Australia. Previous to this, her roles included Program Director – Executive Strategy Delivery for Firmenich SA in Switzerland; and Program Manager - APAC Network Transformation for Caterpillar in Australia.

ENDS

**For more information contact:** David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800

**For media assistance, please contact:** Jackie Ellis, P: +64 27 246 2505 E: [jackie@ellisandco.co.nz](mailto:jackie@ellisandco.co.nz)

### **OVERVIEW** [www.pacifedge.co.nz](http://www.pacifedge.co.nz) [www.pacifedgedx.com](http://www.pacifedgedx.com)

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies.

### **ABOUT Cxbladder Triage** [www.cxbladder.com](http://www.cxbladder.com)

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

**ABOUT Cxbladder Detect** [www.cxbladder.com](http://www.cxbladder.com)

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

**ABOUT Cxbladder Monitor** [www.cxbladder.com](http://www.cxbladder.com)

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

**ABOUT Cxbladder Resolve** [www.cxbladder.com](http://www.cxbladder.com)

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to [www.cxbladder.com](http://www.cxbladder.com) for more information.